The analysts argue that pressure to improve margins and become the partner of choice to hospitals favors large deals.
Is bigger better? McKinsey predicts the return of large medtech mergers Read More »
El tabaco y la marihuana generan importantes riesgos de salud para sus respectivos consumidores. Pero ¿qué ocurre cuando habitualmente se consumen ambos productos? Y, en particular, ¿cómo afecta ese consumo conjunto al cerebro humano? Un nuevo estudio ha buscado una respu …
The nonprofit giant is the latest healthcare organization trying to position itself as an attractive partner for independent physicians who want to transition to value-based payment arrangements.
CommonSpirit launches value-based management platform for physicians Read More »
Presidents of the American Academy of Family Physicians and the American College of Physicians argue for reforms in the national physician payment system.
El mundo se mueve hacia lo verde y renovable, por lo menos ese es el objetivo que se están marcando las instituciones europeas. A pesar de ello, las inversiones que se realizan en todo el mundo relacionadas con los combustibles fósiles no siguen esa tendencia. Aun así, hay mucho …
Los antibióticos han sido un salvavidas médico durante casi un siglo, transformando la atención médica y salvando innumerables vidas. Sin embargo, su uso excesivo e inadecuado ha desencadenado una creciente amenaza global: la resistencia a los antibióticos. Veamos …
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer, a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body.
ZyVersa Therapeutics, Inc. announces publication of a paper in the peer-reviewed Journal of Clinical Investigation highlighting how inflammation in the kidneys can trigger inflammation in the heart.
Faron Pharmaceuticals Ltd. announces that the extraordinary general meeting of the Company took place , September 22, 2023 in Turku, Finland.
Merck, known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer.
